Agoracom Blog Home

Archive for the ‘Featured’ Category

« Older Entries
Newer Entries »

InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, September 8th, 2020
Innocan-Blog

Iris Bincovich, CEO of InnoCan Pharma Corp, shares with Cannabis Report World an overview on how they are disrupting the cannabis world through pharmaceutical innovation and gives us a preview of some of their latest projects one of which is targeting the COVID-19 virus.

Can you introduce us to InnoCan? Where did the idea for the concept originate from?

InnoCan Pharma Corporation is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals.

The founders and officers of InnoCan, all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

InnoCan Pharma was established by Yoram Drucker, an Israeli serial entrepreneur with experience of founding companies in the field of stem cells; Ron Mayron Former CEO of Teva Israel. Teva Pharmaceutical is one of the largest generic drug producers in the world; Nir Avram, our topicals formulator, who was on the pharmaceutical innovation team at Perrigo, he holds a number of patents and has more than 30 years of experience developing topicals; and I bringing a world-wide experience in healthcare with nearly 20 years of international marketing, business development and sales experience. I have led and managed hundreds of successful international transactions in the OTC, cosmetics and dermatology sector.

InnoCan was established as a Pharma company, to enhance the therapeutic properties of CBD, developing unique synergistic delivery systems and OTC/cosmetic products.

Some of our latest projects and products: InnoCan with the Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both Central Nervous System (CNS) indications and the Covid-19 Corona Virus using CBD-loaded Exosomes.

CBD-loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

In addition, InnoCan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection.

Together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, we plan to test the liposome platform on several potential indications.

InnoCan Pharma also develops and manufactures OTC products: R&G Relief & Go – a breakthrough patent-pending CBD pain relief brand, integrating CBD with other pharmaceutical ingredients.

InnoCan’s Pain relief spray provides fast action muscle relaxant and pain relief. It contains an analgesic blend of active ingredients with pure CBD to provide temporary relief of muscle and joint pain.

We also developed a line of Premium derma cosmetic CBD-integrated anti-aging product lines: SHIR, where its formulations feature a tailored blend of active ingredients and technology.

Can you tell us more about your innovative products?

1) Our latest project is a collaboration targeting the COVID-19 virus with Tel Aviv University and Professor Daniel Offen, who heads The Laboratory for Neurosciences at the Felsenstein Medical Research Center.

We are developing an inhalable treatment based on exosomes loaded with CBD, designed to target COVID-19 infected lung cells and might be applicable also to central nervous system diseases.

Exosomes have the ability to target damaged cells like a targeted missile, they improve regeneration and assist in their recovery. CBD is a known anti-inflammatory substance.

Exosomes have been studied for their cell recovery actions and inflammation targeting.  CBD-loaded exosomes (“CLX”) may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. The CBD loaded exosomes are expected to be administered by inhalation.

Together with Professor Offen, an experienced researcher on cell and gene therapy in neurodegenerative diseases, we are looking to develop a new technology that might be applicable to several indications. Prof. Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics (traded on NASDQ, symbol BCLI), developed cell treatment for ALS patients, and is now in Phase III clinical trial.

2) In addition, we are advancing a platform for injectable CBD loaded liposomes in collaboration with Prof. Barenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem. This accurate, controlled administration of CBD by injection, is expected to be as easy as injecting insulin.

Upon every administration of CBD Oil, about 80% of the CBD is being throwed of by enzymes in the liver.  CBD Oil is not easily absorbed, only 5-10 % is ultimately being absorbed.  Patients may be overloaded to achieve a therapeutic level.

CBD is an oily molecule that normally cannot be easily injected into the body.  But once isolated inside a capsule, such as a Liposome, it could be injected.  Liposomes are small vesicles, that could entrap substance inside. The Liposomes technology is planned to enable increase bioavailability and control dosage and provide controlled release of CBD over time.

We are developing a platform for several potential indications.

For example, for people who are suffering from chronic pain, we may be able to offer an injection once a week, and over time, one could have a consistent release of CBD into the body.

Professor Barenholz has already developed a Liposome based breast cancer drug, named Doxil, that was licensed by Johnson & Johnson based on royalties from revenues.

InnoCan Pharma is collaborating with leading researchers’ leader in their fields.

This is one of few value-driven propositions of the company.

3) Innocan Pharma™ leverages extensive knowledge and understanding of the synergistic combination of CBD and FDA-Approved active ingredients for fast-acting relief of severe and acute pain.

R&G is a fast action muscle relaxant and pain relief brand and contains an analgesic blend of active ingredients with CBD. The brand provides temporary relief of muscle and joint pain.

These are EU-GMP manufactured products, clinically tested for safety

This PATENT PENDING UNIQUE FORMULATION combines the known benefits of CBD, Magnesium, Camphor and Menthol to relieve pain, help relax and recover after performing like professionals.

Combining these 4 ingredients at high concentrations, and developing a stable product is highly challenging.  So how does it work? Here is some science:

  • CBD- CBD is a potent antioxidant with anti-inflammatory properties. CBD is known to have a positive effect on pain and reduce swelling.
  • Menthol–a topical analgesic (pain reliever). Menthol produces a cooling sensation by stimulating the skin’s thermos-receptors, which send the brain a signal that is interpreted as cold, numbing effect.
  • Magnesiumchloride – is a known muscle relaxant and food supplement. We developed it into an easy-to-absorb form that may be able to raise levels of this nutrient within the body when applied topically to the skin.
    • The magnesium, absorbed through the skin, is claimed to relieve muscle pains and aches and to enhance relaxation.
  • Camphor- Assists to relieve pain and swelling and inflammation, and preventing skin redness.

4) Dermo cosmetic products powered by science, inspired by nature. SHIR, our beauty & science skincare brand combines the benefits of CBD with the most effective ingredients in innovative formulas to deliver visible fast acting results.

InnoCan Pharma has developed several premium lines of derma cosmetic products containing a tailor blend of highly concentrated ingredients, formulated with CBD. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.

Can you describe the consumer’s behaviour towards cannabis – integrated pharmaceuticals?

As far as we know consumers are waiting to integrate Innocan Pharma’s innovation into their routine.

What challenges have you faced so far in the cannabis market and how were these overcome?

InnoCan Pharma disrupts the Cannabis world. As a pharmaceutical company, we do not grow nor extract, we focus on research and development of drug delivery platforms combining pure cannabidiol with Synergistics delivery systems of ingredients. Our challenge was to distinguish ourselves as a pharma company with highest quality standards to provide consumer confidence.

What so you see happening over the next few years regarding pharma products? What is your general prediction for the sector?

As a pharmaceutical company we predict that the Cannabis industry will move towards a much more regulated industry. Our prediction is that we will see more companies offering variety of products that combine cannabinoids among their ingredients.

What are the plans for the future and your ultimate goal?

To become a Global Leader in Cannabinoid-Integrated Pharmaceutical Products and to Improve the quality of life.

Source: https://cannabisreportworld.com/innocan-developing-revolutionary-products-that-harness-the-unique-properties-of-cannabinoids-combined-with-smart-delivery-formulations/

Tags: , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

VIDEO – Avicanna $AVCN.ca Is Delivering The Vertically Integrated Cannabis Company That Others Failed To $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 9:13 PM on Monday, September 7th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

The Tortoise and the Hare is the famous fable most of us grew up with that teaches this very important lesson – you can be more successful by doing things slowly and steadily than by acting quickly and carelessly.  Said another way, slow and steady wins the race. 

Avicanna (AVCN:TSX) (AVCNF:OTCQB) (0NN:Frankfurt) is the Hare.  The company very few paid attention to because it started off the Cannabis stock market race slowly and surely, while all the other rabbits ran so quickly to win the race that they ended up tripping over themselves or getting so exhausted they couldn’t finish the race. 

You know who those companies are.  All flash, big promises, big promotions, big stock prices ….. and HUGE disappointments. 

Avicanna has surpassed all of them and is starting to pick up speed.  When Avicanna says it is vertically integrated, it isn’t a buzz word, it’s the real story with 4 fully operating divisions that are hitting on all cylinders including, Tier-1 National Partnerships, Global Distribution, Medical Acceptance and History Making Sales. 

Here is a snapshot of what we are referring to, followed by an incredible interview with CEO, Aras Azadian, whose quiet confidence sends the following powerful message –  

“Watch Us Cross The Finish Line” 

CONSUMER RETAIL – COSMETICS 

  • The Only Known CBD Cosmetics Backed By Clinical Trials
  • Full Line Of High End CBD Based Skin Care Products
  • Already Commercializing In Colombia
  • Global Distribution In H2 2020 In United States, Europe and Canada
    • Canadian Distribution Through Shoppers Drug Mart

MEDICAL CANNABIS

  • Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
    • Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
  • Successfully launched advanced products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart
  • Global Distribution Through US, U.K, Australia, Colombia in H2 2020

      PHARMACEUTICALS

  • A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
  • 3 Products Already As Far As PHASE 2

      CULTIVATION

  • 500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia First Ever Export Of Feminized Hemp Seeds From Colombia (To United States).
  • 7,000,000 Seeds For $380,000Additional 75,000,000 Seeds Available For Export In Several Pending Transactions 

Q2 HIGHLIGHTS

  • Revenue increased 172% from $260,903 in Q1 2020 to $709,468 in Q2 2020, and a substantial increase from $16,571 in Q2 2019, coupled with 8% cost reduction from Q1 2020, and 31% cost reduction from Q2 2019

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Avicanna Inc., Featured | Comments Off on VIDEO – Avicanna $AVCN.ca Is Delivering The Vertically Integrated Cannabis Company That Others Failed To $KHRN.ca $TRUL.ca $VFF.ca

PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:09 PM on Friday, September 4th, 2020
  • Signed an $11.5MM contract to provide PyroGenesis’ waste destruction systems
  • Contract is for two Systems, one for each ship in the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).
  • Includes a first payment of approx. $4.8MM
  • With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM

MONTREAL, Sept. 04, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that, further to its press release dated July 9th, 2020, it has signed an $11.5MM contract (the “Contract”) to provide PyroGenesis’ waste destruction systems (the “Systems”). This Contract is for two Systems, one for each ship in the US Navy’s two-ship build.

This Contract includes a first payment (“Down Payment”) of approx. $4.8MM. This project should be completed within 18 months. With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).  

“It is indeed an honor to supply our high-tech products to such a prestigious client as the US Navy. It speaks to our credibility as an innovator with a proven capability of delivering proprietary plasma processes to high value niche markets. Furthermore, it is also a testimony to the fact that PyroGenesis continues to develop commercial cutting-edge applications,” said P. Peter Pascali, President and CEO of PyroGenesis. “This backlog is quite significant particularly when taken in the context of the Company’s previous revenues (2019: $4.8MM, 2018: $5.0MM), and we look forward to adding to this in the very near future.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
www.pyrogenesis.com

Tags: , , , , , , , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 2:42 PM on Friday, September 4th, 2020
  • Signed an $11.5MM contract to provide PyroGenesis’ waste destruction systems
  • Contract is for two Systems, one for each ship in the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).
  • Includes a first payment of approx. $4.8MM
  • With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

MONTREAL, Sept. 04, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that, further to its press release dated July 9th, 2020, it has signed an $11.5MM contract (the “Contract”) to provide PyroGenesis’ waste destruction systems (the “Systems”). This Contract is for two Systems, one for each ship in the US Navy’s two-ship build.

This Contract includes a first payment (“Down Payment”) of approx. $4.8MM. This project should be completed within 18 months. With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).  

“It is indeed an honor to supply our high-tech products to such a prestigious client as the US Navy. It speaks to our credibility as an innovator with a proven capability of delivering proprietary plasma processes to high value niche markets. Furthermore, it is also a testimony to the fact that PyroGenesis continues to develop commercial cutting-edge applications,” said P. Peter Pascali, President and CEO of PyroGenesis. “This backlog is quite significant particularly when taken in the context of the Company’s previous revenues (2019: $4.8MM, 2018: $5.0MM), and we look forward to adding to this in the very near future.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
www.pyrogenesis.com

Tags: , , , , , , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Esports Entertainment Group $GMBL to Present at the 9th Annual Gateway Conference on September 10, 2020 $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 8:36 AM on Friday, September 4th, 2020
  • Invited to present at the 9th Annual Gateway Conference, which is being held virtually on September 9-10, 2020.
  • management is scheduled to present on Thursday, September ­10th at 7:00 a.m. Pacific time, with one-on-one meetings to be held throughout the conference.
  • The presentation will be webcast live and available for replay here.

BIRKIRKARA, MALTA / September 4, 2020 / Esports Entertainment Group, Inc. (NASDAQ:GMBL)(NASDAQ:GMBLW) (or the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, has been invited to present at the 9th Annual Gateway Conference, which is being held virtually on September 9-10, 2020.

Esports Entertainment Group management is scheduled to present on Thursday, September ­10th at 7:00 a.m. Pacific time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay here.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].

About the Gateway Conference 

The 9th Annual Gateway Conference is an invite-only conference presented by Gateway Investor Relations, a full-service financial communications firm. The conference was created to bring together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features a long list of companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. Follow the Gateway Conference on Twitter and join the conversation using the #GatewayIRConference hashtag. For more information, visit gatewayir.com/conference.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fixed odds wagering, fantasy and pools on various esports events in a licensed, regulated and secure platform at vie.gg and owns and operates online sports book, SportNation.bet. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multiplayer mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in the UK, Ireland, Malta and Curacao. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

Contact:

U.S. Investor Relations 
RedChip Companies, Inc.
Dave Gentry
407-491-4498
[email protected]

Media & Investor Relations Inquiries

AGORACOM
[email protected]
http://agoracom.com/ir/eSportsEntertainmentGroup

Tags: , , , ,
Posted in Esports Entertainment Group, Esports Entertainment Group Inc., eSports Investing, Featured | Comments Off on Esports Entertainment Group $GMBL to Present at the 9th Annual Gateway Conference on September 10, 2020 $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Avicanna $AVCN.ca $AVCNF Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 8:31 AM on Friday, September 4th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom
  • Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.
  • The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom
  • The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production

TORONTO, Sept. 4, 2020 – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“), the Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom. The Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives. 

The Company also announces that it has amended and refiled its interim financial statements for the period ended June 30, 2020 (the “Interim Financial Statements”) which amend the Company’s interim financial statements for the same period originally filed on SEDAR on August 14, 2020. At the request of the Ontario Securities Commission, the Interim Financial Statements have been updated to include comparative financial information for the corresponding interim period in the immediately preceding financial year as such information was inadvertently omitted in the initial filing. The changes are for presentation purposes and no figures have been restated. The Company has updated the Statement of Changes in Equity to include the immediately preceding financial year June 30, 2019 balances as required by Section 4.3(2)(b) of National Instrument 51-102 – Continuous Disclosure Obligations.

The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom. The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production. The CBD water soluble formula is part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products. The CBD-based cosmetics were manufactured using CBD produced by SMGH and formulas developed by Avicanna.

The Colombian Ministry of Health granted SMGH a supplementary fabrication quota to receive 1.4 tons of dry flower and transform them into approximately 150 kg of psychoactive derivatives which will be used for commercial exports.

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. 

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including: 

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and, 
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data. 

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company. 

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to complete additional exports of  CBD water soluble formula to the United States, the ability of the Company to complete additional exports of CBD-based cosmetics in to the United Kingdom, the ability of the Company to continue manufacturing CBD-based cosmetics using CBD produced by SMGH, the ability of SMGH to receive 1.4 tons of dry flower for the purposes of extracting psychoactive derivatives, and the ability of SMGH to produce 150 kg of psychoactive derivatives. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , ,
Posted in Avicanna Inc., Featured | Comments Off on Avicanna $AVCN.ca $AVCNF Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements $KHRN.ca $TRUL.ca $VFF.ca

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Engages sagecomm to Market BioCloud $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:25 AM on Friday, September 4th, 2020
kontrol-logo

Kontrol BioCloud is a Safe Space Technology –

  • Announced that sagecomm, a leading marketing communications firm, has been engaged to share the BioCloud story across the country
  • sagecomm is a leading strategic marketing and communications firm whose principals have more than 20 years of progressive experience in marketing-communications in both public and private environments, including education, technology, healthcare, banking, non-profit, and government sectors
  • “Following the completion of several important development milestones we feel the time is appropriate to share our story and our technology development to a larger audience through the media,” says Paul Ghezzi, CEO of Kontrol.

TORONTO, ON / September 4, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that sagecomm, a leading marketing communications firm, has been engaged to share the BioCloud story across the country.

“Following the completion of several important development milestones we feel the time is appropriate to share our story and our technology development to a larger audience through the media,” says Paul Ghezzi, CEO of Kontrol. “We look forward to working with the sagecomm team.”

About sagecomm

sagecomm is a leading strategic marketing and communications firm whose principals have more than 20 years of progressive experience in marketing-communications in both public and private environments, including education, technology, healthcare, banking, non-profit, and government sectors.

“We are impressed with the Kontrol team and excited about the potential of BioCloud and look forward to creating a growing audience for Kontrol,” added Jeff Sage, Co-Founder and Senior Strategist at sagecomm.

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.


Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. 

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated. 

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. 

SOURCE: Kontrol Energy Corp.

Tags: , , , , ,
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Engages sagecomm to Market BioCloud $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Datametrex $DM.ca Receives Largest #COVID19 Test Kits Order to Date for $1.6M From a Canadian Mining Company

Posted by AGORACOM-JC at 10:45 AM on Thursday, September 3rd, 2020
http://www.smallcapepicenter.com/DM%20square.png
  • Announced the largest purchase order to date from a Canadian Mining Company with operations worldwide
  • P.O. is for 50,000 1drop Inc.
  • P.O. is for their Peru and Surinam mining operations.
  • Total gross sales amount is approximately $1.6M CAD, excluding shipping and courier fees
  • COVID-19 test kits manufactured by 1drop Inc. 

TORONTO, Sept. 03, 2020 — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce the largest purchase order (the “P.O.”) to date from a Canadian Mining Company (the “Purchaser”) with operations worldwide. The P.O. is for 50,000 1drop Inc. This P.O. is for their Peru and Surinam mining operations. The total gross sales amount is approximately $1.6M CAD, excluding shipping and courier fees. The P.O. is for 50,000 COVID-19 test kits manufactured by 1drop Inc. 

Under the terms of the P.O., Datametrex will provide the Purchaser with an initial 50,000 units of the COVID-19 qPCR Detection Kits manufactured by 1drop Inc. (“1drop”), 50,000 Universal Transport Medium (UTM®), Sterile Swabs with 16x100mm and Skirted Tubes. The Company is also shipping two (2) Real-Time Polymerase Chain Reaction Detection System (“PCR”) machines along with software to ensure optimal assay performance of the samples, and 50,000 RNA extraction kits.

Datametrex anticipates that it has little or no upfront costs associated with the sale of these test kits.  All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites in Peru and Surinam.

A publicly available survey provided by Statista with sources from Johns Hopkins University (CSSE), World Bank, and Insee, states that Peru is the most impacted country with the most deaths per million (908.8 deaths per million, at the date of this news release – source: https://bit.ly/3bikTRo). Also, Peru is the number two copper producer in the world and with the mining stoppages from the COVID-19 pandemic, combined with operational issues, mine output has declined by 23% over the first five months, with April and May registering declines of 33% and 41%, respectively, as stated by the International Copper Study Group recently reported – source: https://bit.ly/3i64Qc5

“Datametrex is glad to be able to help companies in Peru deal with this urgent situation. Assisting with the implementation of test kits is a fundamental response to the pandemic, and those mining companies that have been able to test more comprehensively have had greater success dealing with the pandemic,” says Marshall Gunter, CEO of the Company. “The reasoning is simple: An individual who tests positive can be isolated until they recover, and their contacts may be traced and similarly tested and isolated, effectively reducing the rate of transmission. We hope our technologies, combined with everyone’s efforts, contribute to the mitigation of the spread in operational mining sites.”

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Receives Largest #COVID19 Test Kits Order to Date for $1.6M From a Canadian Mining Company

VIDEO: FansUnite $FANS.ca Launches U.S. Gambling Expansion, With First Customers Expected In 2020 $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 8:45 AM on Thursday, September 3rd, 2020

The global online gambling market could potentially hit $1 TRILLION by the end of this decade. That isn’t a typo and the reasons are pretty clear – more jurisdictions are legalizing online gambling to get their hands on the tax revenue and the remaining 40% of people on the planet without internet access are going to get it.  

Until recently, however, small-cap investors did not have a company that could provide them ground floor exposure to this massive market and its growth over the next 10 years.  The industry was dominated by the big traditional gambling companies, who focus heavily on old fashioned gambling. 

That all changes with FansUnite, the small cap iGaming super company that goes beyond simple gambling and attacks both sides of the iGaming market by offering both B2C and B2B gambling platforms. 

More than just lip service, the formation of this iGaming super company became a reality when FansUnite acquired Askott Entertainment recently, the highlights of which are as follows:  

  • $27,000,000 Acquisition
  • Over $350,000,000 In Total Bets
  • Over 300,000 Registered Users
  • Strong Emphasis On Esports
  • Over 6,000 Casino Games Onto Platform
  • $5,000,000 Financing In Support Of The Acquisition
  • World Renowned Team

…. And now FANS just entered the US market in record time thanks to a partnership that saved them 12-24 months and millions and millions of dollars.

If you are looking for a disruptive technology company that is well positioned to carve out its share of the massive online gambling world, then you need to watch or listen to our interview with FANS CEO, Scott Burton.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , ,
Posted in AGORACOM Via Satellite, FansUnite Entertainment Inc., Featured | Comments Off on VIDEO: FansUnite $FANS.ca Launches U.S. Gambling Expansion, With First Customers Expected In 2020 $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Kontrol $KNR $KNR.ca $KNR.c $KNRLF provides COVID-19 Technology Update $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:22 AM on Thursday, September 3rd, 2020
kontrol-logo
  • Kontrol BioCloud a Safe Space Technology™
  • During the week of August 31, 2020 Kontrol continued lab testing on its fully operating prototype to validate certain components required for commercialization of BioCloud
  • The testing continues to demonstrate positive results as previously reported in the press release dated August 27, 2020.
  • live COVID-19 testing has been rescheduled to the week of September 8th in order to secure ample time slots in the independent lab
  • To align with the completion of COVID-19 live testing, Kontrol anticipates having 5 functioning BioCloud units that can operate in real-time in the coming weeks

TORONTO, ON / September 3, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its Kontrol BioCloud (or “BioCloud“) technology.

Lab Testing with Prototype and Dormant COVID

During the week of August 31, 2020 Kontrol continued lab testing on its fully operating prototype to validate certain components required for commercialization of BioCloud. The testing continues to demonstrate positive results as previously reported in the press release dated August 27, 2020.

“Through additional testing we are in a position where we can determine that our detection chamber and fully operational prototype continue to deliver positive results against COVID-19 in its dormant form,” says Paul Ghezzi, CEO Kontrol. “In addition, we have enhanced supply chain certainty over all material components required for commercialization.”

Live COVID-19 Testing

The live COVID-19 testing has been rescheduled to the week of September 8th in order to secure ample time slots in the independent lab.

Prototypes and Function Units

To align with the completion of COVID-19 live testing, Kontrol anticipates having 5 functioning BioCloud units that can operate in real-time in the coming weeks.

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.


Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF provides COVID-19 Technology Update $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

« Older Entries
Newer Entries »